Navigation Links
BioMarin Announces First Quarter 2011 Financial Results
Date:4/28/2011

linical Programs

  • BMN-111 for Achondroplasia: BioMarin expects to initiate a Phase I trial by the first quarter of 2012.  BMN-111 is an analog of C-type Natriuretic Peptide (CNP), a small cyclic peptide that is a positive regulator of bone growth, for achondroplasia, the most common form of dwarfism.  There are approximately between 18,000 and 24,000 patients in the U.S. and Europe, 25 percent of which is the estimated addressable market.
  • Other early stage programs: BioMarin is working on multiple early development opportunities.

  • Non-GAAP Financial Information and ReconciliationThe above results for the three months ended March 31, 2011 and March 31, 2010 and financial guidance for the year ending December 31, 2011 are presented both as determined in accordance with GAAP and on a non-GAAP basis. As used in this release, non-GAAP income is based on GAAP Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) adjusted to exclude non-cash stock compensation expense, contingent consideration expense and certain nonrecurring material items (adjusted EBITDA).  

    The following tables detail the reconciliation of non-GAAP to GAAP financial metrics:

    Reconciliation of GAAP Net Income (Loss) to Non-GAAP Adjusted EBITDA(in millions)(unaudited) Three Months EndedMarch 31, Year Ending December 31, 2011 NOTES20112010GuidanceGAAP Net Income (Loss)$
    (4.4)$
    .2$(52) - $(42)Interest expense, net1.41.26Income tax expense4.80.615Depreciation4.73.424Amortization0.90.14EBITDA (Loss)7.46.5(3) - 7Stock-based compensation10.48.543Gain on sale of equity investments-(0.9)-Contingent consideration

    (1)(0.5)0.711Adjusted EBITDA$
    7.3$
    4.8$51 - $61(1)  Represents the changes in the fair value of contingent acquisition consideration payable for the period.BioMarin believes that this non-GAAP information is useful to investors, taken in conjunction with BioMarin's GAAP information bec
    '/>"/>

    SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
    2. BioMarin Announces FDA Approval for Kuvan
    3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
    4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
    5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
    6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
    7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
    8. BioMarin to Present at the Oppenheimer Healthcare Conference
    9. BioMarin Announces Third Quarter 2009 Financial Results
    10. BioMarin to Acquire LEAD Therapeutics
    11. BioMarin to Present at the Credit Suisse Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... Aug. 29, 2014 Medina Medical announced today ... member of the Board of Directors on August 18, ... development and commercialization experience, including over a decade of ... served as a Partner of the medical device incubator ... of two Foundry start-ups. Mr. Engelson previously served as ...
    (Date:8/29/2014)... Aug. 29, 2014 Thoratec Corporation (NASDAQ: ... circulatory support therapies to save, support and restore failing ... 2014 Morgan Stanley Global Healthcare Conference on Wednesday, September ... and Chief Executive Officer, will provide an update on ... (9:55 a.m., Pacific Daylight Time).   A ...
    (Date:8/29/2014)...  BC Technical, the nation,s leading non-OEM provider of ... leader in sales, service and installation of GE MRI ... to continue to expand their resources and inventory while ... "We are committed to driving higher ... president and CEO of BC Technical. "We set out ...
    Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2BC Technical Acquires Polaris Medical Imaging 2
    ... 2007 /PRNewswire-FirstCall/ -- On Wednesday,July 11, 2007, ... European Time members of Cell Therapeutics, Inc.'s ... to discuss today's,announcement of the interim results ... to CPOP-R, in which pixantrone is substituted ...
    ... in a physicians office practice, can be instrumental ... ailments; UTIs, diabetes, several cancers, metabolic disorders, cardiovascular ... for urinalysis tests is well in excess of ... For such a fundamental, extensive and economically significant ...
    Cached Medicine Technology:Cell Therapeutics, Inc. Management to Discuss Today's Announcement,of Interim Pixantrone Study Results 2Urinalysis Analyzers: Large Capabilities in Every Size Device 2Urinalysis Analyzers: Large Capabilities in Every Size Device 3
    (Date:8/29/2014)... review of clinical trials based on administering antidepressants ... concluded that more trials are needed to determine ... pain on a regular basis., Dr. Ian Gilron, ... in the Department of Anesthesiology, and his team ... whether the use of antidepressants for pain relief ...
    (Date:8/29/2014)... by the Mental Health Commission of Canada identifies ... education that police personnel receive. , "People with ... police community, and today,s report builds on the ... with mental illnesses," says Queen,s adjunct professor Dorothy ... the area of police psychology. "This is a ...
    (Date:8/29/2014)... US Preventive Services Task Force recommendations for screening and ... may be ameliorated through technological approaches according to a ... published online August 21, 2014 in the Journal ... David Levine, MD, MA, a third year resident in ... colleagues found that compared to usual care, technology-assisted interventions ...
    (Date:8/29/2014)... New York, New York (PRWEB) August 29, 2014 ... died from cardiac arrest following a series of dialysis ... that alleges her death was the result of ... Liebhard LLP reports. The family’s lawsuit, which was file ... 2014, claims that the use of the products resulted ...
    (Date:8/29/2014)... 29, 2014 A team of experts ... is on its way to the 2014 National Safety ... Convention Center to exhibit and demonstrate a suite of ... industrial environments. Etymotic’s safety earphones and high-definition earplugs are ... at the show. , The company’s HD5 high-definition, ...
    Breaking Medicine News(10 mins):Health News:Antidepressants show potential for postoperative pain 2Health News:Report advocates improved police training 2Health News:Options for weight loss your primary care doctor might not know about 2Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 4Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2
    ... Operating Cash Flow of $173 Million, and Generates $98 ... to Reflect Year-to-Date Sales Results, Maintains Bottom-Line GuidanceAUSTIN, Texas, ... WFMI ) today reported results for the 12-week ... the quarter were $1.9 billion, in line with the ...
    ... clinical trial led by Dr. Katherine Borden, at the ... the Universit de Montral, has shown that a common ... of cancer patients. Published in the journal Blood ... the activities of the eIF4E gene in patients. This ...
    ... American Pathologists today joined a lawsuit against the U.S. Patent and ... for the genes known as BRCA1 and BRCA2, which are indicators ... ... Washington, D.C. (Vocus) May 13, 2009 -- The College of ...
    ... the findings of a landmark drug comparison study published in ... other medications for high blood pressure. A scientific team including ... Houston reports the findings in the May 11 issue of ... in three adults in the United States has high blood ...
    ... be the newest "Biggest Loser" but she is a real ... is about simple, everyday choices that can help you be ... the glass and is one of the simplest things you ... and athletes to don a ,stache for the National Milk ...
    ... combination medication approved with the extended-release form of ... Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, ... announced that the U.S. Food and Drug Administration ... medication ACTO plus met(R) (pioglitazone HCl and ...
    Cached Medicine News:Health News:Whole Foods Market Reports Second Quarter 2009 Results 2Health News:Whole Foods Market Reports Second Quarter 2009 Results 3Health News:Whole Foods Market Reports Second Quarter 2009 Results 4Health News:Whole Foods Market Reports Second Quarter 2009 Results 5Health News:Whole Foods Market Reports Second Quarter 2009 Results 6Health News:Whole Foods Market Reports Second Quarter 2009 Results 7Health News:Whole Foods Market Reports Second Quarter 2009 Results 8Health News:Whole Foods Market Reports Second Quarter 2009 Results 9Health News:Whole Foods Market Reports Second Quarter 2009 Results 10Health News:Whole Foods Market Reports Second Quarter 2009 Results 11Health News:Whole Foods Market Reports Second Quarter 2009 Results 12Health News:Whole Foods Market Reports Second Quarter 2009 Results 13Health News:Whole Foods Market Reports Second Quarter 2009 Results 14Health News:Whole Foods Market Reports Second Quarter 2009 Results 15Health News:Whole Foods Market Reports Second Quarter 2009 Results 16Health News:Whole Foods Market Reports Second Quarter 2009 Results 17Health News:Whole Foods Market Reports Second Quarter 2009 Results 18Health News:Whole Foods Market Reports Second Quarter 2009 Results 19Health News:Whole Foods Market Reports Second Quarter 2009 Results 20Health News:Whole Foods Market Reports Second Quarter 2009 Results 21Health News:Novel therapy may prove effective in treatment of 30 percent of cancers 2Health News:CAP Joins Landmark Lawsuit Challenging Legality of Myriad Genetics Gene Patents 2Health News:New research confirms milestone study on blood pressure meds 2Health News:New research confirms milestone study on blood pressure meds 3Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 2Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 3Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 4
    Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
    Micro emulsifying needles, 18G....
    Micro 2000, micro scissors micro 2000 supercut....
    Yasargil clip applying forceps Mini. Stainless steel jaw....
    Medicine Products: